Recently, immune checkpoint‐inhibitors targeting the programmed cell death 1 (PD‐1)/programmed cell death ligand 1 (PD‐L1) have been shown to improve survival in advanced NSCLC.15, 16, 17, 18. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.